Healthcare ❯ Pharmaceuticals ❯ Clinical Trials ❯ Cancer Treatments

Melanoma

Regeneron Slides as Melanoma Combo Fails to Beat Keytruda in Phase 3

The miss triggered target cuts alongside a securities investigation into prior comments.

Moderna, Merck Melanoma Vaccine Shows Durable Five-Year Benefit as Stock Hits 52-Week High